
    
      A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical
      Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of
      a commercially available influenza vaccine versus Two 0.25 mL Intramuscular Doses of a
      commercially available influenza vaccine in Healthy Children
    
  